Roy D. Baynes
Independent DirectorDr. Roy D. Baynes, MB.BCh., M.Med., Ph.D., FCP, FACP, M.D., is an Independent Director of Aardvark Therapeutics, Inc. since December 18, 2024. Dr. Baynes is Independent Non-Executive Director of Adcendo ApS from April 2025. He serves as Independent Director of CATALYM GmbH since January 2024. He served as Member of Medical Advisory Board at Nurix Therapeutics, Inc. since 2023 until February 2025 and is its Independent Director from March 2025. He has been Executive Vice President and Chief Medical Officer at Eikon Therapeutics, Inc. since joining in July 11, 2022. Dr. Baynes served as Head of Global Clinical Development and Chief Medical Officer at Merck & Co., Inc until April 1, 2022. He served as Chief Medical Officer & Head of Global Clinical Development of Merck Research Laboratories at Merck & Co., Inc. Dr. Baynes served as Senior Vice President and Head of Global Clinical Development at Merck Research Laboratories, the research division of Merck and Co., Inc. since December 2013. Prior to Merck, Dr. Baynes served as Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences, Inc. from January 2012 to December 2013. Dr. Baynes served as Senior Vice President of Oncology Therapeutics at Gilead Sciences Inc. Dr. Baynes joined the Division of Hematology in the Department of Medicine at the University of Kansas Medical Center where he served as Professor of Medicine in both hematology and bone marrow transplantation. Prior to Gilead, Dr. Baynes held positions of increasing responsibility at Amgen Inc., from August 2002 to January 2012 and served as Vice President of Global Clinical Development and Therapeutic Area of Head Hematology & Oncology. He served as Vice President of Oncology for Supportive Care of Amgen Inc. since August 4, 2005. He served as Senior Director, Medical Affairs--Oncology TA of Amgen. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research and director of the Bone Marrow Transplant Program, the Stem Cell Biology Program, the JP McCarthy Umbilical Cord Stem Cell Bank and the Hematological Malignancies Multidisciplinary Clinic at the Barbara Ann Karmanos Cancer Institute, a NCI designated comprehensive cancer center, at Wayne State University, Detroit, Michigan, where he also held the positions of Professor of Medicine and Professor of Oncology. He is Advisor to Board at CATALYM GmbH since 2023. He has been Independent Director of Natera, Inc. since July 25, 2018 and served as Director at Atara Biotherapeutics, Inc. since September 2018 until December 2022. He has been an Independent Director of Travere Therapeutics, Inc. (formerly known as Retrophin, Inc.) since June 2016. Dr. Baynes has authored more than 150 publications and is a member or fellow of several international medical societies. He is a member or fellow of several medical societies and has published more than 200 peer-reviewed articles and abstracts. Dr. Baynes received his medical degree and MB, BCh (Bachelor of Medicine and Surgery) from the University of Witwatersrand, where he also received an MMed (specialist registration) and completed a PhD exploring mechanisms of human iron metabolism from the University of the Witwatersrand in South Africa and completed his medical training in the Department of Hematology and Oncology at Johannesburg Hospital.
Positions
- Company NameAardvark Therapeutics, Inc.Stock CodeAARDPositionIndependent DirectorColleagues
- TLTien-Li LeeCEO, Secretary & Chairman
- NBNelson B. SunCFO & COO
- MSManasi Sinha JaimanChief Medical Officer
- DSDvorit SamidExecutive Vice President of Medical Affairs
- ZZZhenhuan ZhengChief Research Officer
- CCChien-Chuen ChiLead Independent Director
- VEVictor E. TongIndependent Director
- SESusan E. GrafIndependent Director
- Company NameEikon Therapeutics, Inc.Stock CodeEIKNPositionExecutive VP & Chief Medical OfficerColleagues
- RMRoger M. PerlmutterChairman, President & CEO
- MAMichael A. KlobucharChief Operating Officer
- RDRoy D. BaynesExecutive VP & Chief Medical Officer
- RTRobert TjianCo-Founder & Member of Scientific Advisory Board
- EBEric BetzigCo-Founder & Member of Scientific Advisory Board
- KCKenneth C. FrazierIndependent Director
- RLRobert Luther HuffinesIndependent Director
